NEWAMSTERDAM PHARMA COMPANY's ticker is and the CUSIP is N62509109. A total of 30 filers reported holding NEWAMSTERDAM PHARMA COMPANY in Q2 2023. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $22,387,891 | -0.1% | 1,165,429 | +23.0% | 0.01% | 0.0% |
| Q1 2024 | $22,409,014 | +51.3% | 947,527 | -28.5% | 0.01% | +66.7% |
| Q4 2023 | $14,812,571 | +53.3% | 1,326,103 | +26.9% | 0.01% | +20.0% |
| Q3 2023 | $9,664,252 | +117.6% | 1,044,784 | +179.7% | 0.01% | +150.0% |
| Q2 2023 | $4,441,533 | +593687.8% | 373,552 | +571.5% | 0.00% | – |
| Q1 2023 | $748 | – | 55,633 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FCPM III SERVICES B.V. | 11,831,461 | $227,282,366 | 33.52% |
| Bain Capital Life Sciences Investors, LLC | 10,473,913 | $201,203,869 | 22.09% |
| Medicxi Ventures Management (Jersey) Ltd | 2,869,565 | $55,124,344 | 16.44% |
| Frazier Life Sciences Management, L.P. | 12,226,943 | $234,879,575 | 10.99% |
| Cormorant Asset Management, LP | 2,300,000 | $44,183,000 | 2.55% |
| Decheng Capital LLC | 400,000 | $7,684,000 | 2.36% |
| RA Capital Management | 8,064,000 | $154,909,440 | 2.05% |
| SUPERSTRING CAPITAL MANAGEMENT LP | 64,213 | $1,233,532 | 1.56% |
| Opaleye Management Inc. | 315,000 | $6,051,150 | 1.38% |
| Affinity Asset Advisors, LLC | 423,155 | $8,128,808 | 0.94% |